Skip to main content
. Author manuscript; available in PMC: 2024 Dec 1.
Published in final edited form as: Pharmacol Ther. 2023 Nov 10;252:108561. doi: 10.1016/j.pharmthera.2023.108561

Table 3:

Key questions for future studies

1. Can RXR agonists be developed to preferentially target immune cells?
2. Because RXR is a central nuclear receptor that heterodimerizes with other NRs, can the binding to a specific NR be skewed by pharmacological agonists to change the immune cell populations that are targeted?
3) What are the biological effects of RXR activation in T cells and dendritic cells within the tumor microenvironment compared to autoimmune and neurodegenerative diseases?
4) What are the functions of RXR and RXR activation in resident vs. infiltrating immune populations?
5) What are the consequences of RXR agonists in cancer cells since they do not appear to induce apoptosis directly, at least in vitro?
6) Can bexarotene or new RXR agonists be combined with immunotherapy to increase response in patients with cancer?